Successful Therapy Using Pasireotide Long-acting Release for Cushing's Disease Merged with Biochemical Acromegaly

Intern Med. 2021 Apr 1;60(7):1047-1053. doi: 10.2169/internalmedicine.4663-20. Epub 2020 Nov 9.

Abstract

It is quite rare that Cushing's disease shows acromegaly, and no pharmacotherapy has yet been discussed. A 21-year-old woman was diagnosed with Cushing's disease and underwent trans-sphenoidal surgery. Five years later, she was diagnosed with recurrent Cushing's disease and biochemical acromegaly because of elevated levels of serum growth hormone (GH), plasma insulin-like growth factor-1, plasma adrenocorticotropic hormone (ACTH), and the 24-hour urinary excretion of free cortisol. After treatment initiation with pasireotide-long-acting release (LAR), both the ACTH and GH declined. Our case is the first to show the efficacy of pasireotide-LAR in controlling both Cushing's disease and acromegaly.

Keywords: Cushing's disease; acromegaly; pasireotide long-acting release (LAR); plurihormonal pituitary adenoma; somatostatin analog.

Publication types

  • Case Reports

MeSH terms

  • Acromegaly* / complications
  • Acromegaly* / drug therapy
  • Adrenocorticotropic Hormone
  • Adult
  • Female
  • Humans
  • Pituitary ACTH Hypersecretion* / complications
  • Pituitary ACTH Hypersecretion* / drug therapy
  • Somatostatin / analogs & derivatives
  • Young Adult

Substances

  • Somatostatin
  • Adrenocorticotropic Hormone
  • pasireotide